跳至主要内容
临床试验/CTIS2024-511626-30-00
CTIS2024-511626-30-00进行中(未招募)1 期

MEtformin as a MEtabolic iNTervention in Oesophageal adenocarcinomas to improve response to neoadjuvant chemoradiotherapy - MEMENTO

Amsterdam UMC Stichting0 个研究点目标入组 14 人开始时间: 2024年4月19日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
14

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • Surgical resectable (, Adult patients (age = 18 years)., ECOG performance status 0 or 1 (cf. Appendix A)., Adequate hematological, renal and hepatic functions defined as: oAbsolute Neutrophil Count = 1.5 x 109/L oplatelets = 100 x 109/L ohaemoglobin = 5.6 mmol ototal bilirubin = 1.5 x upper normal limit ocreatinine clearance (Cockroft) > 30 ml/min, Patients must be willing to undergo two endoscopies for investigational purposes., Written, voluntary informed consent, Patients must be accessible to follow up and management in the treatment center

排除标准

  • Patients diagnosed with diabetes mellitus type 1 or 2 receiving anti-diabetic drugs., Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) precluding major surgery., Pulmonary fibrosis, active, non-infectious pneumonitis and/or severely impaired lung func-tion precluding major surgery and/or radiation., Serious underlying medical condition which would impair the ability of the patient to re-ceive the planned treatment, including prior allergic reactions to drugs containing Cremo-phor, such as teniposide or cyclosporine., Dementia or altered mental status that would prohibit the understanding and giving of in-formed consent, Patients prescribed metformin or another anti-diabetic drug for any reason., Patients allergic or intolerant to metformin., Previous systemic therapy or radiotherapy on the oesophagus., Severe renal impairment (CLcr = 30 ml/min)., Past (within 5 years) or current history of malignancy other than entry diagnosis interfering with prognosis of esophageal cancer, Previous systemic therapy for other forms of cancer within the last six months., Patients with prior allogeneic stem cell or solid organ transplantation, Pregnancy (positive serum pregnancy test), planning to become pregnant, and lactation.

研究者

相似试验